<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">0416575</journal-id>
<journal-id journal-id-type="pubmed-jr-id">7769</journal-id>
<journal-id journal-id-type="nlm-ta">Toxicol Appl Pharmacol</journal-id>
<journal-id journal-id-type="iso-abbrev">Toxicol. Appl. Pharmacol.</journal-id>
<journal-title-group>
<journal-title>Toxicology and applied pharmacology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0041-008X</issn>
<issn pub-type="epub">1096-0333</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30521819</article-id>
<article-id pub-id-type="pmc">7172934</article-id>
<article-id pub-id-type="doi">10.1016/j.taap.2018.12.001</article-id>
<article-id pub-id-type="manuscript">NIHMS1552635</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Metabolome-wide association study of anti-epileptic drug treatment during pregnancy</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Walker</surname>
<given-names>Douglas I.</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="author-notes" rid="FN1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Perry-Walker</surname>
<given-names>Kayla</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Finnell</surname>
<given-names>Richard H.</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pennell</surname>
<given-names>Kurt D.</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tran</surname>
<given-names>Vilinh</given-names>
</name>
<degrees>MS</degrees>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>May</surname>
<given-names>Ryan C.</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>McElrath</surname>
<given-names>Thomas F.</given-names>
</name>
<degrees>MD/PhD</degrees>
<xref ref-type="aff" rid="A7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Meador</surname>
<given-names>Kimford J.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="A8">8</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pennell</surname>
<given-names>Page B.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="A9">9</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jones</surname>
<given-names>Dean P.</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1.</label>Department of Environmental Health, Rollins School of Public Health, Emory University, Atlanta GA</aff>
<aff id="A2"><label>2.</label>Clinical Biomarkers Laboratory, Division of Pulmonary, Allergy, and Critical Care Medicine, Emory University School of Medicine, Atlanta, GA</aff>
<aff id="A3"><label>3.</label>Department of Obstetrics–Gynecology, Pennsylvania Hospital, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA</aff>
<aff id="A4"><label>4.</label>Departments of Molecular and Cellular Biology and Medicine, Baylor College of Medicine, Houston, TX</aff>
<aff id="A5"><label>5.</label>School of Engineering, Brown University, Providence, RI</aff>
<aff id="A6"><label>6.</label>The Emmes Corporation, Rockville MD</aff>
<aff id="A7"><label>7.</label>Division of Maternal–Fetal Medicine, Department of Obstetrics–Gynecology, Brigham &amp; Women’s Hospital, Harvard Medical School, Boston MA</aff>
<aff id="A8"><label>8.</label>Department of Neurology, Stanford University, Stanford CA</aff>
<aff id="A9"><label>9.</label>Department of Neurology, Brigham and Women’s Hospital, Harvard Medical School, Boston MA</aff>
<author-notes>
<corresp id="CR1"><bold>Name and Address for Correspondence:</bold> Dean P. Jones, Ph.D., Department of Medicine, Pulmonary Division, Emory University, 205P Whitehead Biomedical Research Building, 615 Michael Street, Atlanta, GA 30322, Telephone: 404-727-5970, <email>dpjones@emory.edu</email></corresp>
<fn fn-type="present-address" id="FN1">
<label>*</label>
<p id="P1">Now at: Department of Environmental Medicine and Public Health, Icahn School of Medicine at Mount Sinai, New York, NY</p>
</fn>
<fn fn-type="COI-statement" id="FN2">
<p id="P30"><bold>Potential conflicts of interest:</bold> Dr. Meador has received research support from Sunovion Pharmaceuticals and travel support from UCB Pharma. The Epilepsy Study Consortium pays Dr. Meador’s university for his research consultant time related to Eisai, GW Pharmaceuticals, NeuroPace, Novartis, Supernus, Upsher-Smith Laboratories, UCB Pharma, and Vivus Pharmaceuticals. All remaining authors declare no actual or potential conflicts of interests.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>1</day>
<month>2</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>04</day>
<month>12</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="ppub">
<day>15</day>
<month>1</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>21</day>
<month>4</month>
<year>2020</year>
</pub-date>
<volume>363</volume>
<fpage>122</fpage>
<lpage>130</lpage>
<!--elocation-id from pubmed: 10.1016/j.taap.2018.12.001-->
<abstract id="ABS1">
<p id="P2">Pregnant women with epilepsy (PWWE) require continuous anti-epileptic drug (AED) treatment to avoid risk to themselves and fetal risks secondary to maternal seizures, resulting in prolonged AED exposure to the developing embryo and fetus. The objectives of this study were to determine whether high-resolution metabolomics is able to link the metabolite profile of PWWE receiving lamotrigine or levetiracetam for seizure control to associated pharmacodynamic (PD) biological responses. Untargeted metabolomic analysis of plasma obtained from 82 PWWE was completed using high-resolution mass spectrometry. Biological alterations due to lamotrigine or levetiracetam monotherapy were determined by a metabolome-wide association study that compared patients taking either drug to those who did not require AED treatment. Metabolic changes associated with AED use were then evaluated by testing for drug-dose associated metabolic variations and pathway enrichment. AED therapy resulted in drug-associated metabolic profiles recognizable within maternal plasma. Both the parent compounds and major metabolites were detected, and each AED was correlated with other metabolic features and pathways. Changes in metabolites and metabolic pathways important to maternal health and linked to fetal neurodevelopment were detected for both drugs, including changes in one-carbon metabolism, neurotransmitter biosynthesis and steroid metabolism. In addition, decreased levels of 5-methyltetrahydrofolate and tetrahydrofolate were detected in women taking lamotrigine, which is consistent with recent findings showing increased risk of autism spectrum disorder traits in PWWE using AED. These results represent a first step in development of pharmacometabolomic framework with potential to detect adverse AED-related metabolic changes during pregnancy.</p>
</abstract>
<kwd-group>
<kwd>Epilepsy</kwd>
<kwd>Folate</kwd>
<kwd>High-resolution mass spectrometry</kwd>
<kwd>Lamotrigine</kwd>
<kwd>Levetiracetam</kwd>
<kwd>Pharmacometabolomics</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>